Conjugates for treating diseases caused by PSMA expressing cells
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
1. A conjugate having a formula B-L-(D) n , or a pharmaceutically acceptable salt thereof;
wherein B is a radical of a prostate-specific membrane antigen (PSMA) binding ligand having the formula
wherein * is the point of attachment to L;
L is a polyvalent linker comprising an aminomethylphenylacetic acid diradical; an alkylene substituted with one or more substituents X 1 selected from the group consisting of aryl, substituted aryl, arylalkyl, and substituted arylalkyl; and a cyclic structure selected from the group consisting of a cyclic ether, a cyclic amine, a heterocycle, an arylene, and a heteroarylene;
wherein D is a positron emission tomography (PET) imaging agent; and
wherein n is 1 .
2. The conjugate or a pharmaceutically acceptable salt thereof of claim 1 , wherein the linker further comprises one or more amino acids.
3. The conjugate or a pharmaceutically acceptable salt thereof of claim 1 , wherein the positron emission tomography (PET) imaging agent is an 18 F group covalently attached to the polyvalent linker.
4. The conjugate or a pharmaceutically acceptable salt thereof of claim 1 , wherein the conjugate comprises a fluoroaryl group selected from the group consisting of fluorophenyl, difluorophenyl, and fluoronitrophenyl.
5. A pharmaceutical composition comprising a conjugate of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient, or a combination thereof.